Substituted beta carbolines

US6627637B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Olaf Ritzeler · Bad Soden, DE
• Alfredo C. Castro · Woburn, US
• Louis Grenier · Medford, US
• Francois Soucy · Stoneham, US
• Wayne W. Hancock · Philadelphia, US
• Hormoz Mazdiyashi · Douglas, US
• Vito J. Palombella · Needham, US
• Julian Adams · Ridgefield, US

Key dates

• Filing date: Mar 15, 2001
• Grant date: Sep 30, 2003
• Expiry date: Mar 24, 2021

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&kgr;B kinase is involved.